Ind-Swift Past Earnings Performance
Past criteria checks 2/6
Ind-Swift has been growing earnings at an average annual rate of 24.8%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 9.7% per year.
Key information
24.8%
Earnings growth rate
24.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 9.7% |
| Return on equity | n/a |
| Net Margin | 6.3% |
| Next Earnings Update | 14 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ind-Swift makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,729 | 298 | 782 | 0 |
| 30 Sep 23 | 4,769 | 437 | 759 | 0 |
| 30 Jun 23 | 4,648 | 438 | 710 | 0 |
| 31 Mar 23 | 4,110 | 260 | 717 | 0 |
| 31 Dec 22 | 4,147 | -318 | 707 | 0 |
| 30 Sep 22 | 4,125 | -375 | 690 | 0 |
| 30 Jun 22 | 4,020 | -319 | 648 | 0 |
| 31 Mar 22 | 4,018 | -200 | 661 | 0 |
| 31 Dec 21 | 3,898 | -320 | 664 | 0 |
| 30 Sep 21 | 3,902 | -272 | 656 | 0 |
| 30 Jun 21 | 3,852 | -245 | 590 | 0 |
| 31 Mar 21 | 3,597 | -298 | 604 | 0 |
| 31 Dec 20 | 3,517 | -171 | 577 | 0 |
| 30 Sep 20 | 3,451 | -277 | 563 | 0 |
| 30 Jun 20 | 3,407 | -254 | 515 | 0 |
| 31 Mar 20 | 3,369 | -191 | 565 | 0 |
| 31 Dec 19 | 3,280 | -4 | 568 | 0 |
| 30 Jun 19 | 2,843 | 48 | 506 | 0 |
| 31 Mar 19 | 2,952 | 82 | 542 | 0 |
| 31 Mar 18 | 2,733 | -504 | 501 | 0 |
| 31 Mar 17 | 2,658 | -3,727 | 547 | 0 |
| 31 Dec 16 | 2,778 | -4,000 | 569 | 0 |
| 30 Sep 16 | 2,775 | -2,393 | 571 | 0 |
| 30 Jun 16 | 2,832 | -1,935 | 410 | 0 |
| 31 Mar 16 | 3,043 | -2,136 | 544 | 0 |
| 31 Dec 15 | 3,141 | -1,303 | 877 | 5 |
| 30 Sep 15 | 3,067 | -1,548 | 884 | 5 |
| 30 Jun 15 | 3,205 | -1,550 | 372 | 0 |
| 31 Mar 15 | 4,188 | -1,451 | 561 | 0 |
| 31 Dec 14 | 4,583 | -898 | 1,112 | 7 |
| 30 Sep 14 | 4,979 | -774 | 1,128 | 7 |
| 30 Jun 14 | 6,088 | -945 | 445 | 0 |
| 31 Mar 14 | 5,730 | -1,156 | 1,143 | 7 |
| 31 Dec 13 | 5,839 | -1,594 | 1,088 | 5 |
| 30 Sep 13 | 5,761 | -1,673 | 1,115 | 5 |
| 30 Jun 13 | 2,707 | -1,275 | 687 | 0 |
Quality Earnings: 524652 has a large one-off gain of ₹608.2M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 524652 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524652 has become profitable over the past 5 years, growing earnings by 24.8% per year.
Accelerating Growth: 524652 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524652 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 524652's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.